Latest News

Filters close
Released: 17-Sep-2022 1:05 PM EDT
Novel TEER Repair Device Meets Primary Endpoint in Treating Degenerative Mitral Regurgitation in Patients Not Eligible for Surgery
Cardiovascular Research Foundation (CRF)

Results of the first randomized controlled trial to directly compare two contemporary transcatheter edge-to-edge repair (TEER) devices for degenerative mitral regurgitation (DMR) found that the PASCAL transcatheter valve repair system was non-inferior compared with MitraClip in patients with significant symptomatic DMR who are not eligible for mitral valve surgery. Findings from the CLASP IID trial were reported today at TCT 2022, the 34th annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Released: 17-Sep-2022 1:05 PM EDT
STS/ACC TVT Registry Analysis Assesses Use of Transcatheter Edge-to-Edge Repair in Severe Mitral Regurgitation and Cardiogenic Shock
Cardiovascular Research Foundation (CRF)

An analysis from the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry found that most patients with severe mitral regurgitation (MR) and cardiogenic shock (CS) who underwent mitral transcatheter edge-to-edge repair (TEER) in the United States achieved successful MR reduction, and that successful repair was associated with lower mortality and heart failure (HF) hospitalizations at one year post-procedure compared with unsuccessful repair.

Released: 24-Aug-2022 11:15 AM EDT
CRF and Fogarty Innovation Announce Agenda For TCT MedTech Innovation Forum
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that the program is now available for the TCT MedTech Innovation Forum. The summit will be held on the first day of TCT, the annual scientific symposium of CRF, on Friday, September 16. TCT will take place September 16-19, 2022, in Boston, Massachusetts, at the Boston Convention and Exhibition Center.

Released: 15-Aug-2022 9:35 AM EDT
New educational alliance between the American Heart Association and the Cardiovascular Research Foundation announced
Cardiovascular Research Foundation (CRF)

Two leaders in cardiovascular disease science, research and education, the American Heart Association (Association) and the Cardiovascular Research Foundation (CRF), are joining forces to strengthen and expand educational opportunities focused on advancing the latest research in cardiovascular disease and interventional therapies. The new alliance to produce joint education programs begins immediately with the organizations’ annual scientific meetings this fall. The Association will present educational programming from its annual Scientific Sessions at TCT, and CRF will deliver educational programming from its annual scientific symposium Transcatheter Cardiovascular Therapeutics (TCT) at the Association’s Scientific Sessions, beginning with TCT 2022, September 16-19 in Boston, and the Association’s Scientific Sessions 2022, November 5-7 in Chicago, respectively.

Released: 4-Aug-2022 11:55 AM EDT
CRF Announces TCT 2022 Late-Breaking Clinical Science
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) has announced the late-breaking clinical science that will be presented at TCT 2022. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place September 16-19 in Boston, Massachusetts at the Boston Convention and Exhibition Center.

Released: 27-Jul-2022 2:20 PM EDT
TCT 2022 Career Achievement Award to be Presented to Valentin Fuster, MD, PhD
Cardiovascular Research Foundation (CRF)

The TCT Career Achievement Award will be presented to Valentin Fuster, MD, PhD, on September 17, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). The award is given each year to an outstanding individual who has made significant contributions to the field of interventional cardiology and transformed patient care through their career endeavors, research pursuits, and mentorship of others.

Released: 27-Jul-2022 2:20 PM EDT
TCT 2022 Master Operator Award to Be Presented to Jean Fajadet, MD
Cardiovascular Research Foundation (CRF)

The TCT Geoffrey O. Hartzler Master Operator Award will be presented to Jean Fajadet, MD, on September 18, 2022, at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). The award is given each year to a physician who has advanced the field of interventional cardiovascular medicine through technical excellence and innovation.

Newswise: CRF and Fogarty Innovation Launch the “TCT MedTech Innovation Forum”
Released: 6-Jul-2022 10:05 AM EDT
CRF and Fogarty Innovation Launch the “TCT MedTech Innovation Forum”
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) and Fogarty Innovation announced today that they are joining forces to launch the "TCT MedTech Innovation Forum” just before the main sessions of TCT (Transcatheter Cardiovascular Therapeutics) 2022, the annual scientific symposium of CRF. TCT will be held September 16-19, 2022, in Boston, Massachusetts at the Boston Convention and Exhibition Center.

Released: 13-May-2022 5:05 PM EDT
Late-Breaking Science Announced for TVT 2022
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) announced that TVT: The Structural Heart Summit will feature 12 studies as Late-Breaking Clinical Science and Featured Clinical Research. An annual meeting covering cutting-edge research and techniques for structural heart interventions, TVT will take place June 8-10, 2022, at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.

Released: 10-May-2022 4:05 PM EDT
TVT 2022 Program Now Available
Cardiovascular Research Foundation (CRF)

The program for TVT 2022: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions and will take place June 8-10, 2022 at the Sheraton Grand Chicago Riverwalk in Chicago, Illinois.

Released: 9-May-2022 2:00 PM EDT
Media Registration for TCT 2022 Now Open
Cardiovascular Research Foundation (CRF)

Media registration is now open for TCT 2022 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will be held September 16-19, 2022, in Boston, Massachusetts at the Boston Convention and Exhibition Center.

Released: 10-Feb-2022 10:45 AM EST
CTO Plus 2022 Will Feature Expanded Program
Cardiovascular Research Foundation (CRF)

CTO Plus 2022 will feature the latest research and techniques for chronic total occlusions (CTO) as well as complex percutaneous coronary interventions (PCI). The annual conference, organized by the Cardiovascular Research Foundation (CRF), will take place February 24-25, 2022 at the New York Marriott Marquis in New York, NY. Online access to the live cases and discussions will be complimentary. The full program is now available online.

Released: 13-Jan-2022 5:05 PM EST
THT, CRF’s First-Ever Conference on Technology and Heart Failure Therapeutics, Will Take Place February 1-2, 2022
Cardiovascular Research Foundation (CRF)

The program for THT 2022: Technology and Heart Failure Therapeutics is now available online. THT is the first-ever conference on technology and heart failure therapeutics from the Cardiovascular Research Foundation (CRF). The meeting, which explores new and emerging treatments and innovative monitoring strategies, will take place February 1-2, 2022 online and in person, at the New York Marriott Marquis in New York, NY.

Newswise: image.jpg
Released: 22-Nov-2021 1:45 PM EST
Lungpacer Medical Wins TCT 2021 Shark Tank Innovation Competition
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) is pleased to announce that Lungpacer Medical, a clinical stage medical device company pioneering a diaphragm pacing therapy system for critically ill patients who require mechanical ventilation, has won the TCT 2021 Shark Tank Innovation Competition, which took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine. The winner was also presented with the Jon DeHaan Foundation Award for Interventional Innovation.

Released: 8-Nov-2021 11:40 AM EST
Trial Compares Two Devices Used For Percutaneous Left Atrial Appendage Closure
Cardiovascular Research Foundation (CRF)

SWISS-APERO is the first randomized clinical trial comparing Amulet with the new generation Watchman FLX device in terms of residual left atrial appendage (LAA) patency after percutaneous LAA closure (LAAC) as evaluated by 45-day cardiac computed tomography angiography (CCTA). The study showed that the two devices achieve a similar rate of LAA occlusion at 45 days but through different mechanism. Furthermore, Amulet as compared with Watchman FLX was associated with higher procedural complications but similar clinical outcomes at 45-days.

Released: 8-Nov-2021 11:30 AM EST
Study Examines Differences in Gastrointestinal Effects of Antiplatelet Regimens After PCI
Cardiovascular Research Foundation (CRF)

Utilizing a magnetically-controlled capsule endoscopy system, the double-blind, randomized OPT-PEACE trial found that nearly all patients receiving antiplatelet therapy developed evidence of abnormal gastrointestinal (GI) mucosal findings on capsule endoscopy. Dual antiplatelet therapy (DAPT) followed by single anti-platelet therapy (SAPT) led to less GI injury than continued DAPT.

Released: 8-Nov-2021 11:25 AM EST
Randomized Study Examines Outcomes of Plug-based and Suture-based Vascular Closure Following TAVR Procedures
Cardiovascular Research Foundation (CRF)

Results from the largest randomized trial available comparing different closure device strategies following transcatheter aortic valve replacement (TAVR) found that a plug-based vascular closure technique had a shorter time to hemostasis but a higher rate of access-site or access-related vascular complications.

Released: 8-Nov-2021 8:55 AM EST
Transcatheter Aortic Valve Replacement is Cost Effective Compared With Surgical Replacement for Low-Risk Patients
Cardiovascular Research Foundation (CRF)

An economic analysis of data from PARTNER 3, a randomized trial comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) in patients with severe aortic stenosis and low surgical risk, found that despite higher procedural costs, at 2-year follow-up, quality-adjusted life expectancy was greater and total costs were lower with TAVR; as a result, at 2-years, TAVR was cost-effective for these patients.

Released: 8-Nov-2021 8:55 AM EST
Patients With Diabetes Undergoing PCI Have Less Target Lesion Failure With Amphilimus-eluting Stents
Cardiovascular Research Foundation (CRF)

Results from SUGAR, a randomized, controlled, multicenter trial conducted exclusively in patients with diabetes mellitus (DM) and with minimum exclusion criteria, found that amphilimus-eluting stents (AES) were superior to zotarolimus-eluting stents (ZES) with regard to target lesion and target vessel failure composite outcomes at one year.

Released: 8-Nov-2021 8:50 AM EST
Study Finds That PCI Guided by FFR Did Not Meet Noninferiority for One-Year Outcomes Compared to Bypass Surgery
Cardiovascular Research Foundation (CRF)

The primary results of the Fractional Flow Reserve Versus Angiography for Multivessel Evaluation (FAME) 3 trial found that percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) did not meet noninferiority for one-year adverse events compared to coronary artery bypass grafting (CABG) in patients with three-vessel coronary artery disease. Patients with a low SYNTAX score (which measures the complexity of coronary artery disease) had less incidence of adverse events compared to those with intermediate or high SYNTAX scores, and in this cohort of patients PCI performed more favorably.

Released: 8-Nov-2021 8:50 AM EST
Study Examines Combined Effects of Medical Titration and Renal Denervation Treatment–Resistant Hypertension
Cardiovascular Research Foundation (CRF)

Six-month outcomes from the randomized RADIANCE-HTN TRIO Trial comparing endovascular ultrasound renal denervation (RDN) to a sham procedure for treatment-resistant hypertension (HTN) found that the addition of a pharmacologic intervention led to further blood pressure reductions after RDN with a smaller increase in additional medications prescribed and less use of diuretics.

Released: 8-Nov-2021 8:50 AM EST
Study Finds QFR-Guided Lesion Selection Leads to Better PCI Outcomes Compared with Conventional Angiography
Cardiovascular Research Foundation (CRF)

The FAVOR III China trial found that lesion selection for percutaneous coronary intervention (PCI) using the non-invasively assessed physiologic measurement quantitative flow ratio (QFR) improved outcomes for PCI compared with a standard angiography-guided strategy.

Released: 8-Nov-2021 8:05 AM EST
Intermediate-Risk Patients Have Similar Five-Year Outcomes With Transcatheter Or Surgical Aortic Valve Replacement
Cardiovascular Research Foundation (CRF)

New five-year data from the SURTAVI trial found that there was no difference in all-cause mortality or stroke between patients at intermediate surgical risk who had transcatheter aortic valve replacement (TAVR) or surgery. Although there were initially more reinterventions after TAVR, the rates were similar after two years and key clinical endpoints were also similar.

Released: 26-Oct-2021 1:10 PM EDT
CRF Announces Free Online Access to TCT 2021
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) is pleased to announce that the digital component of TCT 2021 will now be free for the entire interventional community. After careful consideration and achieving a critical level of support, CRF’s leadership has agreed to fully support this initiative. Complimentary online registration will include access to all content via livestream during the meeting and on-demand access for one year.

Released: 6-Oct-2021 8:20 AM EDT
CRF Will Stream Select TCT 2021 Abstract Presentations on Twitter and Facebook During the Month of October
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) will stream select abstracts from Transcatheter Cardiovascular Therapeutics (TCT) 2021 throughout the month of October. These free sessions will be streamed on Twitter and Facebook.

Released: 16-Sep-2021 9:40 AM EDT
CRF Announces TCT 2021 Late-Breaking Trials and Science
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) has announced 22 late-breaking trial and science presentations that will be reported at TCT 2021. TCT is the annual scientific symposium of CRF and the world’s premier educational meeting specializing in interventional cardiovascular medicine. It will take place November 4-6, 2021 in Orlando, Florida at the Orange County Convention Center and simultaneously broadcast live.

Released: 6-Aug-2021 3:05 PM EDT
Media Registration for TCT 2021 Now Open
Cardiovascular Research Foundation (CRF)

Media registration is now open for TCT 2021 (Transcatheter Cardiovascular Therapeutics), the annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT will be held November 4-6, 2021 in Orlando, Florida at the Orange County Convention Center and simultaneously broadcast live.

Released: 2-Jul-2021 1:05 PM EDT
Late-Breaking Science Announced for TVT 2021
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) announced that TVT 2021 will feature 12 studies as Late-Breaking Clinical Science. An annual meeting from CRF, TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.

Released: 26-May-2021 1:25 PM EDT
TVT 2021 Program Now Available
Cardiovascular Research Foundation (CRF)

The program for TVT 2021: The Structural Heart Summit is now available online. An annual meeting from the Cardiovascular Research Foundation (CRF), TVT features cutting-edge research and techniques for structural heart interventions. TVT will take place online and in person, with limited attendance, at the Fontainebleau Miami Beach in Miami Beach, Florida July 20-22, 2021.

Released: 24-Feb-2021 1:50 PM EST
A New Beat Offers Free Online Seminar Examining Disparities in Cardiovascular Care During Heart Month
Cardiovascular Research Foundation (CRF)

The Association of Black Cardiologists, Inc. (ABC) and the Cardiovascular Research Foundation (CRF) is offering a complimentary online seminar, “Tackling Disparities in CV Care: A Closer Look at Hypertension and Heart Failure” on Friday February 26, 2021. The program is part of a joint initiative called A New Beat which advocates for women and minorities rising as leaders in cardiology. It aims to foster careers of female and minority cardiologists, who can be poised to improve access to quality care for underserved populations.

Released: 16-Feb-2021 3:25 PM EST
Heart Valve Collaboratory Announces U.S. Food and Drug Administration Participation in Collaborative Community
Cardiovascular Research Foundation (CRF)

The Heart Valve Collaboratory (HVC) announced today that the U.S. Food and Drug Administration (FDA)’s Center for Devices and Radiological Health (CDRH) will participate in this “collaborative community”. A medical “collaboratory” is a forum in which multidisciplinary private and public sector members work together on medical device challenges to achieve aligned outcomes, solve shared problems, and leverage collective opportunities, in the interest of improving patient care.

Released: 11-Feb-2021 11:30 AM EST
CRF Offers Free Online Seminar to Help People Jump-Start their Heart Health During Heart Month
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) will hold a free online seminar, The Big Three: High Blood Pressure, High Cholesterol, and Diabetes, at 12:00 PM ET on February 22, 2021 hosted by Drs. Nisha Jhalani and Sonia Tolani, cardiologists from NewYork-Presbyterian/Columbia University Irving Medical Center. The seminar is part of a series of “Mini Med Schools” conducted by the CRF Women’s Heart Health Initiative (WHHI), which empowers women with everyday tools they can use to defy heart disease.

Released: 27-Jan-2021 2:50 PM EST
CRF Fellows Course Connect Will Take Place Online May 7-9, 2021
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) has announced that its annual Interventional Cardiology Fellows Course will take place online May 7-9, 2021. The CRF Fellows Course is an interactive educational program introducing advanced interventional cardiology trainees to all facets of coronary, structural, and endovascular interventions.

Released: 6-Jan-2021 1:00 PM EST
David J. Cohen, MD, MSc, Joins CRF as Director of Clinical and Outcomes Research and St. Francis Hospital as Director of Academic Affairs
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) announced today that David J. Cohen, MD, MSc, has joined the organization as Director of Clinical and Outcomes Research.

Released: 4-Dec-2020 11:15 AM EST
Free Access to TCT Connect Extended for One Year
Cardiovascular Research Foundation (CRF)

All educational programming from TCT Connect will be available to registrants for free through October 18, 2021. TCT is the annual scientific symposium of the Cardiovascular Research Foundation (CRF) and the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Released: 17-Nov-2020 3:50 PM EST
CTO 2021 Is Now an Online Event: CTO Connect
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) has announced that the 2021 Chronic Total Occlusion (CTO) Summit will now take place as a virtual event called CTO Connect. It will take place online February 20-21, 2021. The conference will feature live case transmissions performed by some of the world’s leading operators along with real-time analysis from world-class faculty members. Live and on-demand sessions will also highlight engaging case-based discussions, challenging cases, and the latest technical developments and refinements in CTO PCI.

Released: 19-Oct-2020 8:20 AM EDT
Randomized Trial Reports Outcomes with Novel, Low Profile Fixed-Wire Drug-Eluting Stent that Facilitates Transradial Access
Cardiovascular Research Foundation (CRF)

The OPTIMIZE randomized trial comparing a novel, low-profile drug-eluting stent (DES) facilitating transradial access (TR) and direct stenting (DS) to existing DES did not establish non-inferiority of the new stent based on the prespecified study statistical analysis plan, likely due to the definition of periprocedural target vessel myocardial infarction (TVMI) coupled with a large proportion of high-sensitive cardiac troponin assays used in the trial.

Released: 19-Oct-2020 8:20 AM EDT
Randomized Clinical Trial Finds No Mortality Risk or Benefit Associated with Drug-Coated Devices in the Treatment of Peripheral Artery Disease
Cardiovascular Research Foundation (CRF)

A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used.

Released: 19-Oct-2020 8:15 AM EDT
Randomized Trial Comparing a Nano-Coated Coronary Stent and Shorter DAPT Did Not Meet Non-Inferiority Criteria for Thrombotic Events
Cardiovascular Research Foundation (CRF)

For patients undergoing percutaneous coronary intervention (PCI) that also require oral anticoagulation, treatment with a nanotechnology polymer-coated stent plus 14-day dual anti-platelet therapy (DAPT) did not reduce bleeding or establish non-inferior outcomes for thrombotic events compared with a drug-eluting stent (DES) and standard three or six-month DAPT therapy.

Released: 19-Oct-2020 8:05 AM EDT
Randomized Trial Finds that Drug-Eluting Stents With Durable Polymers are Non-Inferior to Those With Biodegradable Polymers
Cardiovascular Research Foundation (CRF)

A randomized clinical trial found that drug-eluting stents (DES) with durable polymers are non-inferior to DES with biodegradable polymers in patients with acute coronary syndrome (ACS). Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Released: 16-Oct-2020 4:55 PM EDT
OnSight Medical Wins TCT Connect 2020 hark Tank Innovation Competition
Cardiovascular Research Foundation (CRF)

The Cardiovascular Research Foundation (CRF) is pleased to announce that OnSight Medical, an AI-based company specializing in cardiac ultrasound imaging, has won the TCT 2020 Shark Tank Innovation Competition which took place during the Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier educational meeting specializing in interventional cardiovascular medicine. The winner was also presented with the Jon DeHaan Foundation Award for Interventional Innovation.

Released: 16-Oct-2020 4:50 PM EDT
Deferral of PCI in FFR-Abnormal Lesions with Preserved Coronary Flow Reserve Is Not Associated with Similar Outcomes as Untreated Lesions with Normal FFR
Cardiovascular Research Foundation (CRF)

A new observational study of deferred lesions following combined fractional flow reserve (FFR) and coronary flow reserve (CFR) assessments found that untreated vessels with abnormal FFR but intact CFR do not have non-inferior outcomes compared to those with an FFR greater than 0.8 and a CFR greater than or equal to two when treated medically.

Released: 16-Oct-2020 4:40 PM EDT
Physiology-guided Percutaneous Coronary Intervention Optimization Strategy May Lead to Improved Outcomes
Cardiovascular Research Foundation (CRF)

Results from the randomized controlled TARGET FFR trial show that while a physiology-guided percutaneous coronary intervention (PCI) optimization strategy did not achieve a significant increase in the proportion of patients with final FFR ≥0.90, it reduced the proportion of patients with a residual FFR ≤0.80 following PCI.

Released: 16-Oct-2020 4:35 PM EDT
Fractional Flow Reserve Derived from Computed Tomography Coronary Angiography Did Not Significantly Reduce Costs But Reduced Rates of Invasive Coronary Angiography
Cardiovascular Research Foundation (CRF)

In the FORECAST randomized clinical trial, the use of fractional flow reserve management derived from computed tomography (FFRCT) did not significantly reduce costs but did reduce the use of invasive coronary angiography (ICA).

Released: 15-Oct-2020 4:50 PM EDT
Trial Finds that Interventional Closure of Residual Atrial Septal Defect One-Month Post Transcatheter Mitral Valve Repair Was Not Superior to Medical Treatment
Cardiovascular Research Foundation (CRF)

The MITHRAS randomized clinical trial found that interventional closure of an iatrogenic atrial septal defect (iASD) driven by transcatheter mitral valve repair (TMVR) was not superior to conservative medical treatment with regard to the primary endpoint of change in six-minute walking distance.

Released: 15-Oct-2020 4:45 PM EDT
Randomized Trial Studies Device Designed to Reduce Embolic Events in Patients Undergoing TAVR
Cardiovascular Research Foundation (CRF)

The REFLECT II randomized clinical trial evaluating the safety and efficacy of a device designed to reduce cerebral embolization and ischemic stroke, complications of transcatheter aortic valve replacement (TAVR), found that the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority of the device for the primary hierarchical efficacy endpoint.

Released: 15-Oct-2020 4:30 PM EDT
New Bioprosthetic Valve for TAVR Fails to Demonstrate Non-Inferiority
Cardiovascular Research Foundation (CRF)

In a randomized clinical trial, SCOPE II, a new self-expanding bioprosthetic valve used in transcatheter aortic valve replacement (TAVR) failed to demonstrate non-inferiority compared to an existing self-expanding valve.

Released: 14-Oct-2020 7:20 PM EDT
Meta-Analysis of Bivalirudin vs. Heparin in Patients with MI Examines Mortality and Bleeding Rates
Cardiovascular Research Foundation (CRF)

An individual patient data pooled analysis comparing the use of bivalirudin versus heparin in heart attack patients undergoing percutaneous coronary intervention (PCI) found that bivalirudin use was associated with similar overall rates of 30-day mortality across all heart attack patients, but lower rates of serious bleeding events. Moreover, mortality was reduced in patients with ST-segment elevation myocardial infarction (STEMI) who were treated with a post-PCI bivalirudin infusion.

Released: 14-Oct-2020 7:15 PM EDT
Combined FFR and OCT Imaging Can Improve Accuracy of High-Risk Lesion Identification in Patients with Diabetes
Cardiovascular Research Foundation (CRF)

Data from COMBINE (OCT-FFR) found that the use of FFR combined with OCT imaging can help improve the accuracy of high-risk lesion identification in patients with diabetes. Findings were reported today at TCT Connect, the 32nd annual scientific symposium of the Cardiovascular Research Foundation (CRF). TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

Released: 14-Oct-2020 7:10 PM EDT
Pilot Randomized Trial Demonstrates that PCI of Non-Flow-Limiting Vulnerable Plaques May be Safe with Favorable Long-Term Clinical Outcomes
Cardiovascular Research Foundation (CRF)

New data from PROSPECT ABSORB, a pilot randomized trial of percutaneous coronary intervention (PCI) of non-flow-limiting vulnerable plaques in native coronary arteries, found that PCI was safe, substantially enlarged follow-up lumen areas, and was associated with favorable long-term clinical outcomes.


Showing results

150 of 178

close
0.39329